[EN] HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS<br/>[FR] TRIAZOLES SUBSTITUÉS PAR HÉTÉROARYLE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
申请人:AMGEN INC
公开号:WO2018097945A1
公开(公告)日:2018-05-31
Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
Hydrogen–deuterium exchange in thiazoles via phase-transfer catalysis
作者:William J. Spillane、Patrick Kavanagh、Frances Young、Henri J.-M. Dou、Jacques Metzger
DOI:10.1039/p19810001763
日期:——
quaternary (ammonium, phosphonium, and arsonium) salts and 17 solvents have been studied. The effect of chain-length of the salt [Me(CH2)n]4[graphic omitted]Br–(n= 1–5) has been examined. First-order kinetics (in thiazole) are reported for seven thiazoles. The present method offers a practical route to specifically and higher deuteriated (D 90%) thiazoles and other aromatics.
[EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS<br/>[FR] COMPOSÉS ET MÉTHODES DE DÉGRADATION CIBLÉE DE KRAS
申请人:ARVINAS OPERATIONS INC
公开号:WO2023141570A2
公开(公告)日:2023-07-27
Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the Von Hippel-Lindau E3 ubiquitin ligase and on the other end a moiety which binds KRAS, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
本文描述了可用作 Kirsten ras 肉瘤蛋白(KRAS)调节剂的双功能化合物。特别是,本公开的杂双官能化合物一端含有与 Von Hippel-Lindau E3 泛素连接酶结合的分子,另一端含有与 KRAS 结合的分子,从而将靶蛋白置于泛素连接酶附近,以实现对靶蛋白的降解(和抑制)。本公开的杂双官能团化合物具有与降解/抑制靶蛋白相关的多种药理活性。本发明公开的化合物和组合物可以治疗或预防由于靶蛋白调节失常而导致的疾病或失调。
Metzger; Koether, Annales Universitatis Saraviensis, Scientia, 1952, vol. 1, p. 23
作者:Metzger、Koether
DOI:——
日期:——
Metzger; Koether, Bulletin de la Societe Chimique de France, 1953, p. 702,705